Effect of Nafamostat on Postreperfusion Syndrome (PRS)

Seoul National University

Status and phase: Completed; Phase 4

Conditions: Liver Transplantation; Postreperfusion Syndrome

Treatments: Drug: Normal saline; Drug: Nafamostat

Study type: Interventional

Funder types: Other

Identifiers

NCT01001403

CWJung_futhan-liver TPL

Details and patient eligibility

About

This study intends to see the effect of nafamostat on the attenuation of postreperfusion syndrome (PRS) that frequently occurs during liver transplantation.

Enrollment: 62 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• >= 18 year old scheduled to undergo liver transplantation

Exclusion criteria

• Previous history of pulmonary, cardiovascular, or renal disease
• Previous history of allergic reactions to nafamostat

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

62 participants in 2 patient groups, including a placebo group

nafamostat

Experimental group

Description:

The Nafamostat mesilate group received 0.2 mg/kg of nafamostat mesilate intravenously 1 min before reperfusion of the liver graft.

Treatment:

Drug: Nafamostat

Control

Placebo Comparator group

Description:

The control group received 10 ml of normal saline (same volume as nafamostat)intravenously 1 min before reperfusion of the liver graft.

Treatment:

Drug: Normal saline